阿戈美拉汀治疗首发抑郁症伴失眠的疗效研究.pdf

世界睡眠医学杂志 2021 年 6 月第 8 卷第 6 期
　938
Wor in each the ef-
fective rates，depression state[Hamilton Depression Scale（HAMD）]，sleep quality[Pittsburgh Sleep quality index（PSQI）]beore
the treatment and at 4th and 8th week after the treatment，REM sleep structure and side reaction[Treatment Emergent Symptom
Scale（TESS）]of two groups were ：The effective rates of two groups were compared，there was no statistically
significant difference（P ＞），the HAMD score and PSQI score of two groups before the treatment were compared，there were no
statistically significant differences（P ＞），the HAMD score of observation group at 4th and 8th week after the treatment were
significantly lower than those of control group，the daytime function and sleep time at 8th week after the treatment were significantly
better than those of control group，REM sleep density was significantly lower than that of control group，REM duration and cycle
were significantly longer than those of control group，the total score of TESS was significantly lower than that of control group，there
were statistically significant differences （P ＜ ）.Conclusion：The agomelatine can significantly improve the depression and
sleep structure of first-episode depression patients with insomnia，and the cur